PFM Health Sciences, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001442756

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 72 positions · Total reported value $1.71B · Top-10 concentration 51.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.8% · 24 new · 28 cut · 39 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.9% · vs SPY -7.0% · Prev Value $1.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.3% · vs SPY +0.2% · Latest Value $978.49M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, PFM Health Sciences, LP disclosed 72 equity positions with a combined reported value of $1.71B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were LLY ($264.58M), THC ($97.96M), CYTK ($92.78M). By sector, the heaviest allocations are Health Care 90.4%, Industrials 5.2%. Versus the prior quarter, allocation shifted toward Health Care (+6.2pp), Industrials (+1.4pp) and away from Other (-7.9pp).

Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 72% of names.

The largest new positions opened in Q3 2024 were INSP ($20.75M), CON ($6.71M), TGTX ($5.46M).

Of the 39 positions fully exited versus the prior quarter, the largest were QQQ ($89.79M), CNC ($39.68M), DXCM ($26.19M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • INSP INSPIRE MED SYS INC · $20.75M
  • CON CONCENTRA GROUP HOLDINGS PAR · $6.71M
  • TGTX TG THERAPEUTICS INC · $5.46M
  • VEEV VEEVA SYS INC · $4.04M
  • LBPH LONGBOARD PHARMACEUTICALS IN · $3.79M
  • OCUL OCULAR THERAPEUTIX INC · $3.50M
  • LUNG PULMONX CORP · $3.06M
  • CAPR CAPRICOR THERAPEUTICS INC · $2.32M

Fully Exited (vs previous quarter)

  • QQQ INVESCO QQQ TR · prev qtr: $89.79M
  • CNC CENTENE CORP DEL · prev qtr: $39.68M · history
  • DXCM DEXCOM INC · prev qtr: $26.19M
  • JNJ JOHNSON & JOHNSON · prev qtr: $18.83M
  • BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $14.91M
  • IWM ISHARES TR · prev qtr: $14.34M · history
  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $8.40M · history
  • APLS APELLIS PH · prev qtr: $3.18M

Insider Transactions (Form 4)

Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-69012 (status: Approved), registered 2008-04-10
  • Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 2 hedge funds
  • Website: pfmhealthsciences.com

Portfolio Structure

  • 96 positions · $1.14B reported value (Q2 2026)
  • Top 10 holdings = 34.6% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
  • Average position size: $11.89M

Sector Tilt

  • Health Care 92.9%
  • Industrials 5.1%
  • Consumer Staples 1.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 32 new, 24 added, 40 reduced, 14 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 90.4%
Materials 0.6%
Technology 0.2%
Other 3.5%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 298.64K $264.58M 15.52%
15.52%
Hold
2 589.41K $97.96M 5.74%
5.74%
Hold
3 1.76M $92.78M 5.44%
5.44%
Hold
4 403.86K $79.75M 4.68%
4.68%
Hold
5 148.85K $69.23M 4.06%
4.06%
Hold
6 137.33K $67.46M 3.96%
3.96%
Hold
7 542.81K $61.64M 3.62%
3.62%
Reduce
8 124.84K $50.74M 2.98%
2.98%
Hold
9 213.98K $49.00M 2.87%
2.87%
Hold
10 97.50K $48.20M 2.83%
2.83%
Hold
11 86.83K $47.07M 2.76%
2.76%
Hold
12 75.59K $44.19M 2.59%
2.59%
Add
13 686.15K $43.51M 2.55%
2.55%
Add
14 467.43K $42.01M 2.46%
2.46%
Hold
15 58.43K $36.14M 2.12%
2.12%
Reduce
16 125.52K $34.90M 2.05%
2.05%
Hold
17 116.53K $33.48M 1.96%
1.96%
Hold
18 166.26K $32.31M 1.89%
1.89%
Reduce
19 101.95K $32.29M 1.89%
1.89%
Reduce
20 56.44K $29.35M 1.72%
1.72%
Add
21 90.30K $29.09M 1.71%
1.71%
Add
22 111.85K $26.51M 1.55%
1.55%
Hold
23 390.86K $25.79M 1.51%
1.51%
Reduce
24 101.68K $24.52M 1.44%
1.44%
Reduce
25 67.01K $24.21M 1.42%
1.42%
Reduce
26 70.09K $24.15M 1.42%
1.42%
Hold
27 98.32K $20.75M 1.22%
1.22%
New
28 51.06K $18.38M 1.08%
1.08%
Add
29 860.82K $18.26M 1.07%
1.07%
Hold
30 2.74M $16.62M 0.97%
0.97%
Reduce
31 90.77K $13.55M 0.80%
0.80%
Reduce
32 4.88M $13.31M 0.78%
0.78%
Add
33 121.84K $12.04M 0.71%
0.71%
Reduce
34 152.23K $11.11M 0.65%
0.65%
Reduce
35 710.25K $10.59M 0.62%
0.62%
Reduce
36 183.09K $10.54M 0.62%
0.62%
Reduce
37 10.00M $9.50M 0.56%
0.56%
Reduce
38 108.47K $9.09M 0.53%
0.53%
Reduce
39 7.75M $8.80M 0.52%
0.52%
Hold
40 4.31M $8.44M 0.49%
0.49%
Add
41 423.91K $8.16M 0.48%
0.48%
Add
42 3.40M $7.21M 0.42%
0.42%
Add
43 179.88K $7.08M 0.41%
0.41%
Add
44 300.00K $6.71M 0.39%
0.39%
New
45 101.05K $5.87M 0.34%
0.34%
Add
46 205.07K $5.74M 0.34%
0.34%
Hold
47 77.39K $5.66M 0.33%
0.33%
Reduce
48 233.41K $5.46M 0.32%
0.32%
New
49 60.60K $5.06M 0.30%
0.30%
Reduce
50 342.17K $4.77M 0.28%
0.28%
Reduce

FAQ

What did PFM Health Sciences, LP buy in 2024-Q3?

In its 2024-Q3 13F filing, PFM Health Sciences, LP reported 72 equity positions worth $1.71B in aggregate; its largest disclosed positions were LLY ($264.58M), THC ($97.96M), CYTK ($92.78M).

How large is PFM Health Sciences, LP's portfolio?

PFM Health Sciences, LP reported $1.71B of long equity holdings across 72 positions as of 2024-Q3. Top-10 holdings account for 51.7% of reported value.

What is PFM Health Sciences, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pfm-health-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →